Clinical trials: Metastatic Gastrointestinal Cancer
Gastrointestinal Stromal Tumor, Sarcoma
Nitrocamptothecin in Treating Patients With Soft Tissue Sarcomas
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of nitrocamptothecin in treating patients who have locally…
- Conditions
- Gastrointestinal Stromal Tumor, Sarcoma, Small Intestine Cancer
- Trial name
- NCT00005874
- Testing
- rubitecan
- Where
- United States
- Sponsor
- Astex Pharmaceuticals, Inc.
Colon Cancer, Rectal Cancer
Clinical Trial in Patients With Metastatic Colorectal Cancer
The objectives of this trial are to determine if CoFactor in combination with 5-FU are effective in the treatment of metastatic colorectal cancer and to determine the side effects observed with the administration of CoFactor and…
- Trial name
- NCT00081627
- Testing
- CoFactor and 5FU
- Where
- 9 sites in United States, Serbia and Montenegro
- Volunteers
- 48 people
- Sponsor
- Mast Therapeutics, Inc.
Colorectal Cancer
A Study to Investigate Efficacy and Safety of Cobimetinib Plus Atezolizumab and Atezolizumab Monotherapy Versus Regorafenib in Participants With Metastatic Colorectal Adenocarcinoma (COTEZO IMblaze370)
This is a Phase III, multicenter, open-label, three-arm, randomized study in participants with unresectable locally advanced or metastatic colorectal cancer (CRC) who have received at least two prior regimens of cytotoxic…
- Trial name
- NCT02788279
- Testing
- Atezolizumab (MPDL3280A), an Engineered Anti-PDL1 Antibody, Cobimetinib, Regorafenib
- Where
- 73 sites in United States, Australia and 9 more
- Volunteers
- 363 people
- Sponsor
- Hoffmann-La Roche
Metastatic Colorectal Cancer
Phase II Efficacy Study of AZD6244 in Colorectal Cancer
The purpose of the study is to assess if there is benefit when using AZD6244 in the treatment if metastatic colorectal cancer in comparison with another treatment called capecitabine.
- Trial name
- NCT00514761
- Testing
- AZD6244, Capecitabine
- Where
- 3 sites in Brazil
- Volunteers
- 64 people
- Sponsor
- AstraZeneca
Colorectal Cancer, Head and Neck Cancer
Combination Study of Urelumab and Cetuximab in Patients With Advanced/Metastatic Colorectal Cancer or Advanced/Metastatic Head and Neck Cancer
The purpose of the study is to determine the safety, tolerability and maximum tolerated dose of Urelumab in combination with Cetuximab in patients with Advanced/Metastatic Colorectal Cancer or Advanced/Metastatic Squamous Cell…
- Trial name
- NCT02110082
- Testing
- Urelumab, Cetuximab
- Where
- 7 sites in United States
- Volunteers
- 66 people
- Sponsor
- Bristol-Myers Squibb
Advanced Solid Tumors
Safety and Efficacy Study in Adults With Advanced Solid Tumors Receiving REGN13089-M404-M2980, an Antibody-drug Conjugate That Targets MET Protein on Tumors
This study will test a Regeneron drug called REGN13089-M404-M2980 ("study drug") to see if it can help treat previously treated, advanced solid tumors (tumors that have grown and spread to different areas of the body).
- Trial name
- NCT07863024
- Testing
- REGN13089-M404-M2980
- Volunteers
- 320 people
- Sponsor
- Regeneron Pharmaceuticals
Esophageal Squamous Cell Carcinoma (ESCC)
QLC5508 vs. Chemotherapy in Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma
This study is designed to assess the efficacy and safety of QLC5508 in patients with unresectable advanced or metastatic esophageal squamous cell carcinoma (ESCC) who have experienced disease progression following treatment with…
- Trial name
- NCT07463573
- Testing
- QLC5508, Investigator's Choice of Chemotherapy (docetaxel, paclitaxel, or Irinotecan Hydrochloride)
- Where
- China
- Volunteers
- 466 people
- Sponsor
- Qilu Pharmaceutical Co., Ltd.
Colorectal Neoplasm
Investigating the Use of Regorafenib (Stivarga®) in Patients With Metastatic Colorectal Cancer (mCRC) After Failure of Standard Therapy
The purpose of the study is to investigate the safety and effectiveness of Stivarga in patients with metastatic colorectal carcinoma in routine use in Germany.
- Trial name
- RECORA (NCT01959269)
- Testing
- Regorafenib (Stivarga, BAY 73-4506)
- Where
- Germany
- Volunteers
- 483 people
- Sponsor
- Bayer
Metastases, Colorectal Neoplasms
Evaluation of the Efficacy of Xaliproden (SR57746A) in Preventing the Neurotoxicity of Oxaliplatin / 5FU/LV Chemotherapy.
Primary Objective : Compare the risk of occurrence of Grade3-4 cumulative peripheral sensory neuropathy (PSN) relative to cumulative dose of oxaliplatin between treatment group and placebo group.
- Conditions
- Metastases, Colorectal Neoplasms, Colorectal Carcinoma
- Trial name
- NCT00305188
- Testing
- Xaliproden (SR57746A), Oxaliplatin, 5-Fluorouracil
- Where
- 13 sites in United States, Argentina and 11 more
- Volunteers
- 879 people
- Sponsor
- Sanofi
Metastatic Colorectal Cancer
Donafenib for Previously Treated Metastatic Colorectal Cancer
The investigators do the clinical trial (patients with metastatic colorectal cancer treated with donafenib/placebo after failure of standard therapy) to assess efficacy and safety of donafenib in patients with metastatic…
- Trial name
- NCT02870582
- Testing
- Donafenib
- Where
- 2 sites in China
- Volunteers
- 536 people
- Sponsor
- Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Brain and Central Nervous System Tumors, Breast Cancer
Yttrium Y 90 SMT 487 in Treating Patients With Refractory or Recurrent Cancer
RATIONALE: Radiolabeled drugs such as yttrium Y 90 SMT 487 can locate tumor cells and deliver tumor-killing substances to them without harming normal cells.
- Conditions
- Brain and Central Nervous System Tumors, Breast Cancer, Gastrointestinal Carcinoid Tumor, Islet Cell Tumor
- Trial name
- NCT00006368
- Testing
- yttrium Y 90-edotreotide
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Novartis Pharmaceuticals
Colorectal Cancer
Safety and Efficacy Study of MEHD7945A + FOLFIRI Versus Cetuximab + FOLFIRI as Second Line Therapy in Participants With KRAS Wild-Type Metastatic Colorectal Cancer (mCRC)
This open-label, randomized, multicenter, Phase 2 study will evaluate the safety and efficacy of MEHD7945A when combined with FOLFIRI (folinic acid [leucovorin], 5-fluorouracil [5-FU], and irinotecan) chemotherapy as compared to…
- Trial name
- NCT01652482
- Testing
- 5-fluorouracil, Cetuximab, Irinotecan
- Where
- 65 sites in United States, Australia and 8 more
- Volunteers
- 135 people
- Sponsor
- Genentech, Inc.
Colorectal Cancer, Neoplasm Metastasis
Circulating Tumor Cells in Patients With Metastatic Colorectal Cancer
This study enrolled patients with measurable metastatic colorectal cancer. Blood was drawn prior to the patient receiving a new therapy for his/her cancer and subsequently at 7-14 days, 3-4 weeks, and when an imaging study was…
- Trial name
- IMMC-06 (NCT00133913)
- Testing
- Phlebotomy
- Where
- United States
- Volunteers
- 486 people
- Sponsor
- Immunicon
Carcinoma, Hepatocellular
A Dose-Finding and Exploratory Study of RO5323441 in Combination With Sorafenib in Patients With Hepatocellular Carcinoma
This open-label study will assess the safety, efficacy and pharmacokinetics of RO5323441 in combination with sorafenib in patients with advanced or metastatic hepatocellular carcinoma previously untreated with systemic therapy.
- Trial name
- NCT01308723
- Testing
- RO5323441, sorafenib
- Where
- 2 sites in Singapore
- Volunteers
- 6 people
- Sponsor
- Hoffmann-La Roche
Breast Cancer Stage III, HER2-positive Metastatic Breast Cancer
Evaluate BL-M17D1 in Patients w/HER2-Expressing/Mutant Advanced or Metastatic Solid Tumors
The objective of this study to evaluate the safety, tolerability, pharmacokinetics, and efficacy of BL-M17D1 in patients with HER2-Expressing or HER2-Mutant Advanced or Metastatic Solid Tumors.
- Conditions
- Breast Cancer Stage III, HER2-positive Metastatic Breast Cancer, Unresectable Breast Carcinoma, Her2-Positive
- Trial name
- NCT06714617
- Testing
- BL-M17D1
- Where
- 9 sites in United States
- Volunteers
- 3 people
- Sponsor
- SystImmune Inc.
Ovarian Cancer, Breast Cancer
Comprehensive Outcomes for After Cancer Health
This study intends to explore feasibility, acceptability, and outcomes related to the use of a digital health coaching intervention for individuals who have completed primary therapy for cancer.
- Conditions
- Ovarian Cancer, Breast Cancer, Lung Cancer, Gastric Cancer
- Trial name
- COACH (NCT05349227)
- Testing
- Digital Health Coaching Program, Fitbit
- Where
- 7 sites in United States
- Volunteers
- 625 people, healthy volunteers welcome
- Sponsor
- Pack Health
Metastatic Liver Cancer, Secondary Liver Cancer
Study Comparing Radio Frequency Ablation Plus Chemotherapy and Chemotherapy Alone in Patients With Secondary Liver Metastases
The purpose of this study is to determine whether patients treated with Radiofrequency Ablation (RFA) in conjunction with chemotherapy have a better overall survival rate than patients treated with chemotherapy alone.
- Conditions
- Metastatic Liver Cancer, Secondary Liver Cancer, Liver Neoplasm
- Trial name
- Prometheus (NCT00510627)
- Testing
- Radiofrequency Ablation (RFA), Chemotherapy
- Where
- 2 sites in United States
- Sponsor
- Boston Scientific Corporation
Colorectal Cancer, Carcinoma
Evaluating ABX-EGF in Patients With Metastatic ColorectalCarcinoma
The purpose of this study is to determine if ABX-EGF is safe and efficacious in patients with metastatic colorectal cancer.
- Trial name
- NCT00111774
- Testing
- ABX-EGF
- Volunteers
- 150 people
- Sponsor
- Amgen
Gastric Cancer, Colon Cancer
Clinical Study of CEA Targeting Chimeric Antigen Receptor T Lymphocytes（CAR-T） for CEA Positive Advanced Malignant Solid Tumors
This study is a open-label, dose-escalating + dose-expansion clinical study, aiming to evaluate the safety and efficacy of CEA-targeted CART cell preparations, and to reliminarily observe the study drug in CEA-positive advanced…
- Conditions
- Gastric Cancer, Colon Cancer, Rectal Cancer, Breast Cancer
- Trial name
- NCT06126406
- Testing
- CEA-targeted CAR-T cells
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Chongqing Precision Biotech Co., Ltd
Metastatic Pancreatic Cancer
Saltikva for Metastatic Pancreatic Cancer
Objectives: Assess the efficacy of multiple dose oral administration of Saltikva, an attenuated strain of Salmonella Typhimurium expressing IL-2, in patients with metastatic pancreatic cancer on standard chemotherapy (either…
- Trial name
- NCT04589234
- Testing
- Salmonella-IL2, FOLFIRINOX Alone (Historical Controls), Gemcitabine/Abraxane Alone (Historical Controls)
- Where
- Canada
- Volunteers
- 60 people
- Sponsor
- Salspera LLC
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.